Tarsier Pharma Ltd. Stock Price

Tarsier Pharma Ltd. operates as a clinical stage biopharmaceutical company in Israel. The company engages in the development and commercialization of novel pharmaceutical therapies for the treatment of ocular diseases with underlying inflammatory pathologies. The company’s dazdotuftide platform technology is a bio -inspired immunomodulator designed to treat blinding inflammatory ocular diseases and is currently being developed as both eye drops and intravitreal injections. Its product candidate, TRS01 is an eye drop formulation of dazdotuftide, a new chemical entity developed for the treatment of non -infectious anterior uveitis including patients diagnosed with glaucoma. Additionally, the company engages in the pre-clinical development of an intravitreal slow-release injection formulation of dazdotuftide known as TRS02 for the treatment of back-of-the-eye retinal diseases, such as DME, NPDR, dry-AMD and back-of-the-eye uveitis. The company was formerly known as Tarsius Pharma Ltd. and changed its name to Tarsier Pharma Ltd. in February 2021. Tarsier Pharma Ltd. was incorporated in 2016 and is based in Zihron Ya'akov, Israel.